Fluvoxamine
≈ 9 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 443824781 | image = Fluvoxamine.svg | image_class = skin-invert-image | width = | alt = | caption = | image2 = Fluvoxamine 3D 4ENH.png | image_class2 = bg-transparent | width2 = | alt2 = | pronounce = UK: US: | tradename = Luvox, others | Drugs.com = | MedlinePlus = a695004 | DailyMedID = Fluvoxamine | pregnancy_AU = C | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = Selective serotonin reuptake inhibitor (SSRI) | ATC_prefix = N06 | ATC_suffix = AB08 | ATC_supplemental = | legal_AU = S4 | legal_AU_comment = | legal_BR = C1 | legal_BR_comment = | legal_CA = Rx-only | legal_CA_comment = | legal_DE = | legal_DE_comment = | legal_NZ = | legal_NZ_comment = | legal_UK = POM | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = | legal_UN = | legal_UN_comment = | legal_status = | bioavailability = 53% (90% confidence interval: 44–62%) | protein_bound = 77–80% | metabolism = Liver (primarily O-demethylation) Major: CYP2D6 or CYP1A2 Minor: CYP3A4, CYP2C19, and/or CYP1A2 | metabolites = | onset = | elimination_half-life = 12–13 hours (single dose), 22 hours (repeated dosing) | duration_of_action = | excretion = Kidney (98%; 94% as metabolites, 4% as unchanged drug) | CAS_number_Ref = | CAS_number = 54739-18-3 | CAS_supplemental = | PubChem = 532434…
{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 443824781 | image = Fluvoxamine.svg | image_class = skin-invert-image | width = | alt = | caption = | image2 = Fluvoxamine 3D 4ENH.png | image_class2 = bg-transparent | width2 = | alt2 = | pronounce = UK: US: | tradename = Luvox, others | Drugs.com = | MedlinePlus = a695004 | DailyMedID = Fluvoxamine | pregnancy_AU = C | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = Selective serotonin reuptake inhibitor (SSRI) | ATC_prefix = N06 | ATC_suffix = AB08 | ATC_supplemental = | legal_AU = S4 | legal_AU_comment = | legal_BR = C1 | legal_BR_comment = | legal_CA = Rx-only | legal_CA_comment = | legal_DE = | legal_DE_comment = | legal_NZ = | legal_NZ_comment = | legal_UK = POM | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = | legal_UN = | legal_UN_comment = | legal_status = | bioavailability = 53% (90% confidence interval: 44–62%) | protein_bound = 77–80% | metabolism = Liver (primarily O-demethylation) Major: CYP2D6 or CYP1A2 Minor: CYP3A4, CYP2C19, and/or CYP1A2 | metabolites = | onset = | elimination_half-life = 12–13 hours (single dose), 22 hours (repeated dosing) | duration_of_action = | excretion = Kidney (98%; 94% as metabolites, 4% as unchanged drug) | CAS_number_Ref = | CAS_number = 54739-18-3 | CAS_supplemental = | PubChem = 5324346 | IUPHAR_ligand = 7189 | DrugBank_Ref = | DrugBank = DB00176 | ChemSpiderID_Ref = | ChemSpiderID = 4481878 | UNII_Ref = | UNII = O4L1XPO44W | KEGG_Ref = | KEGG = D07984 | ChEBI_Ref = | ChEBI = 5138 | ChEMBL_Ref = | ChEMBL = 814 | NIAID_ChemDB = | PDB_ligand = | synonyms = | IUPAC_name = 2- {[(E)- {5-Methoxy-1-[4-(trifluoromethyl)phenyl] pentylidene}amino]oxy}ethanamine | C = 15 | H = 21 | F = 3 | N = 2 | O = 2 | SMILES = FC(F)(F)c1ccc(\C(=N\OCCN)CCCCOC)cc1 | StdInChI_Ref = | StdInChI = 1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+ | StdInChI_comment = | StdInChIKey_Ref = | StdInChIKey = CJOFXWAVKWHTFT-XSFVSMFZSA-N | density = | density_notes = | melting_point = | melting_high = | melting_notes = | boiling_point = | boiling_notes = | solubility = | sol_units = | specific_rotation = }} Fluvoxamine, sold under the brand name Luvox among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is primarily used to treat major depressive disorder and, perhaps more especially, obsessive–compulsive disorder (OCD), but is also used to treat anxiety disorders such as panic disorder, social anxiety disorder, and post-traumatic stress disorder. Fluvoxamine's side-effect profile is similar to that of other SSRIs. Common adverse effects include constipation, gastrointestinal problems, headache, anxiety, irritation, sexual problems, dry mouth, sleep problems, and an increased risk of suicide at the start of treatment. These effects appear to be significantly weaker than with other SSRIs, with the exception of gastrointestinal side-effects. In some patients, sexual dysfunction may persist even after the drug is discontinued, a condition known as post-SSRI sexual dysfunction; regulatory agencies including the European Medicines Agency and Health Canada have recommended that fluvoxamine's product labeling warn of this risk. Fluvoxamine appears to be more tolerable than other SSRIs, particularly with respect to cardiovascular complications. It is on the World Health Organization's List of Essential Medicines.
Medical uses
In many countries (e.g., Australia, the United Kingdom, and Russia ) it is commonly used for major depressive disorder. Fluvoxamine is also approved in the United States for obsessive–compulsive disorder (OCD), and social anxiety disorder. In Japan, it is also approved to treat OCD, social anxiety disorder, and major depressive disorder. Fluvoxamine is indicated for children and adolescents with OCD. The NICE guidelines in the United Kingdom have, as of 2005, authorized its use for OCD in adults and adolescents of any age and children over the age of 7. There is evidence that fluvoxamine is effective for generalised social anxiety in adults, although, as with other SSRIs, some of the results may be compromised by having been funded by pharmaceutical companies. Of the SSRIs, however, fluvoxamine, paroxetine, and sertraline do appear consistent as viable treatments for generalised social anxiety. Fluvoxamine is also effective for treating a range of anxiety disorders in children and adolescents, including generalized anxiety disorder, social anxiety disorder, panic disorder, and separation anxiety disorder. The drug works long-term, and retains its therapeutic efficacy for at least one year. The average therapeutic dose for fluvoxamine is 100 to 300 mg/day, with 300 mg being the upper daily limit normally recommended. OCD, however, often requires higher doses; doses of up to 450 mg/day may be prescribed in this case. The (off-label) upper daily limits for other serotonin-reuptake inhibitors used in the treatment of OCD, by analogy, are 400 mg for sertraline, 100 mg for paroxetine, 120 mg for both fluoxetine and citalopram, 60 mg for escitalopram and 300 mg for clomipramine. In any case with fluvoxamine, treatment is generally begun at 50 mg and increased in 50 mg increments every 4 to 7 days until a therapeutic optimum is reached.
Adverse effects
Fluvoxamine's side-effect profile is very similar to other SSRIs. Gastrointestinal side effects are characteristic of those receiving treatment with fluvoxamine. However, compared to escitalopram and sertraline, fluvoxamine's gastrointestinal profile may be less intense, often being limited to nausea. Mosapride has demonstrated efficacy in treating fluvoxamine-induced nausea. It is also advised practice to divide total daily doses of fluvoxamine greater than 100 mg, with the higher fraction being taken in the evening (e.g., 50 mg at the beginning of the waking day and 200 mg at bedtime). In any case, high starting daily doses of fluvoxamine rather than the recommended gradual titration (starting at 50 mg and gradually titrating, up to 300 mg if necessary) may increase the likelihood of nausea. In comparison to other SSRIs, fluvoxamine has the second highest rate of causing discontinuation syndrome, as a result of the low half-life of fluvoxamine.
Common
Common side effects occurring with 1–10% incidence: Abdominal pain Agitation Anxiety Asthenia (weakness) Constipation Diarrhea Dizziness Dyspepsia (indigestion) Headache Hyperhidrosis (excess sweating) Insomnia Loss of appetite Malaise Nausea Nervousness Palpitations Restlessness Sexual dysfunction (including delayed ejaculation, erectile dysfunction, decreased libido, etc.) Somnolence (drowsiness) Tachycardia (high heart rate) Tremor Vomiting Weight loss Xerostomia (dry mouth) Yawning
Uncommon
Uncommon side effects occurring with 0.1–1% incidence: Arthralgia Confusional state Cutaneous hypersensitivity reactions (e.g. oedema [buildup of fluid in the tissues], rash, pruritus) Extrapyramidal side effects (e.g. dystonia, parkinsonism, tremor, etc.) Hallucination Orthostatic hypotension
Rare
Rare side effects occurring with 0.01–0.1% incidence: Abnormal hepatic (liver) function Galactorrhoea (expulsion of breast milk unrelated to pregnancy or breastfeeding) Mania Photosensitivity (being abnormally sensitive to light) Seizures
Unknown frequency
Akathisia a sense of inner restlessness that presents itself with the inability to stay still Bed-wetting Bone fractures Dysgeusia Ecchymoses Glaucoma Haemorrhage Hyperprolactinaemia (elevated plasma prolactin levels leading to galactorrhoea, amenorrhoea [cessation of menstrual cycles], etc.) Hyponatraemia Mydriasis Neuroleptic malignant syndrome – practically identical presentation to serotonin syndrome except with a more prolonged onset Paraesthesia Serotonin syndrome – a potentially fatal condition characterised by abrupt onset muscle rigidity, hyperthermia (elevated body temperature), rhabdomyolysis, mental status changes (e.g. coma, hallucinations, agitation), etc. Suicidal ideation and behaviour Syndrome of inappropriate antidiuretic hormone secretion Urinary incontinence Urinary retention Violence toward others Weight changes Withdrawal symptoms
Pharmacology
Pharmacodynamics
Fluvoxamine is a potent selective serotonin reuptake inhibitor with around 100-fold affinity for the serotonin transporter over the norepinephrine transporter. It has negligible affinity for the dopamine transporter or any other site, with the sole exception of the σ 1 receptor. It behaves as a potent agonist at this receptor and has the highest affinity (36 nM) of any SSRI for doing so. This may contribute to its antidepressant and anxiolytic effects and may also afford it some efficacy in treating the cognitive symptoms of depression. It increases concentrations of the neurosteroid allopregnanolone, which may also contribute to its anxiolytic effects. Unlike some other SSRIs, fluvoxamine's metabolites are pharmacologically neutral.
Pharmacokinetics
Literature reviews have stated that fluvoxamine is metabolized primarily by CYP2D6 and to a minor extent by CYP1A2. However, CYP2D6 poor metabolizers do not have considerably higher fluvoxamine levels than extensive metabolizers. Fluvoxamine inhibits oxidative drug metabolising enzymes (particularly CYP1A2, and less potently CYP3A4 and CYP2D6) The mean plasma half-life of fluvoxamine after multiple oral doses of 100 mg/day in healthy, young volunteers was 13.6-15.6 hours. In the elderly, however the half life ranged from 17.4 to 25.9. Steady-state plasma fluvoxamine concentrations were 2-3 fold higher in children than in adolescents.
History
Fluvoxamine was developed by Kali-Duphar, part of Solvay Pharmaceuticals, Belgium, now Abbott Laboratories, and introduced as Floxyfral in Switzerland in 1983. It was approved by the U.S. Food and Drug Administration (FDA) in 1994, and introduced as Luvox in the US. In India, it is available, among several other brands, as Uvox by Abbott. It was one of the first SSRI antidepressants to be launched, and is prescribed in many countries to patients with major depression. It was the first SSRI, a non-TCA drug, approved by the U.S. FDA specifically for the treatment of OCD. At the end of 1995, more than ten million patients worldwide had been treated with fluvoxamine. Fluvoxamine was the first SSRI to be registered for the treatment of obsessive compulsive disorder in children by the FDA in 1997. In Japan, fluvoxamine was the first SSRI to be approved for the treatment of depression in 1999 and was later in 2005 the first drug to be approved for the treatment of social anxiety disorder. Fluvoxamine was the first SSRI approved for clinical use in the United Kingdom. Manufacturers include BayPharma, Synthon, and Teva, among others.
Environment
Fluvoxamine is a common finding in waters near human settlement. Christensen et al. 2007 finds it is "very toxic to aquatic organisms" by European Union standards.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1368879073 under CC BY-SA 4.0; modifications have been made.